Health system and cardiovascular leaders discuss implementing Lp(a) testing more consistently across clinical practices. The session explores why Lp(a) levels are an important consideration in comprehensive cardiovascular risk assessment and examines how systems have approached internal alignment, workflow challenges, and integration into routine care. Speakers share implementation lessons and real-world insights for health systems considering a similar approach.
Learnings Include:
- Why some health systems are incorporating Lp(a) testing into comprehensive cardiovascular risk assessment
- Real-world approaches to aligning clinical, operational, and population health stakeholders around testing initiatives
- Where Lp(a) testing was embedded into workflows and what changes were required to operationalize testing consistently across care settings
Lp(a), Lipoprotein (a).
This content is intended for US health care system decision makers only.
Sponsored by Novartis Pharmaceuticals Corporation.
7/26 FA-11731651